Octreotide LAR treatment throughout pregnancy in an acromegalic woman.
We report a 24-year-old woman with active acromegaly despite pituitary surgery and irradiation who received continuous octreotide LAR treatment for the control of GH excess throughout her pregnancy. The patient delivered a healthy girl following an uneventful pregnancy. Despite a substantial materno-fetal transfer of octreotide, postnatal development was normal with length parameters around the 50th percentile at 3 months of age. In almost all previously described cases (n = 13) octreotide was stopped after the diagnosis of pregnancy was established. No side-effects of mother or fetus have been reported. Octreotide treatment in pregnancy seems to be feasible and safe. Due to the still-limited number of reported cases, the potential benefits of octreotide treatment should be weighed carefully against its possible risks.
Fassnacht
M
M
Department of Endocrinology, University of Wuerzburg, Germany. m.fassnacht@medizin.uni-wuerzburg.de
Capeller
B
B
Arlt
W
W
Steck
T
T
Allolio
B
B
D000172:Acromegaly / Q000188:drug therapy*; D000236:Adenoma / Q000188:drug therapy; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008431:Maternal-Fetal Exchange; D015282:Octreotide / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000188:drug therapy; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011295:Prenatal Care / Q000379:methods*
D018931:Antineoplastic Agents, Hormonal; D003692:Delayed-Action Preparations; D015282:Octreotide